NASD · Healthcare · Biotechnology · USA
Regeneron Pharmaceuticals Inc is a large cap company (market value between $10 billion and $200 billion) in the Biotechnology industry.
Regeneron Pharmaceuticals creates and sells pharmaceutical treatments for patients with serious conditions across multiple therapeutic areas including eye disease, cancer, autoimmune disorders, cardiovascular disease, neurological illness, blood disorders, infectious disease, and rare conditions. The company operates through research, development, manufacturing, and commercial operations, often partnering with collaborators like Sanofi and Bayer to bring treatments to market.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Regeneron Pharmaceuticals Inc stock.
Overvalued: intrinsic value $649.96 per share, market price $782.04, margin of safety -20.3% (as of 2026-10-19).
Discounting its cash flows at 9.1% (average of 3 methods) values the shares at $649.96; the price of $782.04 is 20% above that value, and 76% of that value comes from beyond year five.
Leak Score: 40/100 on 12 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
33 more in this industry show a wider margin of safety.
REGN is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 9.1% (average of 3 methods) values the shares at $649.96; the price of $782.04 is 20% above that value, and 76% of that value comes from beyond year five.
$649.96 per share (as of the 2026-10-19 close), against a market price of $782.04. That is a margin of safety of -20.3%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
The price asks for more growth than the company has delivered. It needs the future to beat the past. Yearly sales growth the price needs: 13.9%. Yearly sales growth it has sustained: 7.8%.
40 out of 100, which we rate "On Watch", on 12 of 12 value investing signals.